Biodesix to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
09 2월 2022 - 8:00PM
Business Wire
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic
solutions company with a focus in lung disease, today announced
Scott Hutton, Chief Executive Officer of Biodesix, will present in
a fireside chat at the BTIG MedTech, Digital Health, Life Science
& Diagnostic Tools Conference being held virtually February
15-17, 2022.
BTIG MedTech, Digital Health, Life Science & Diagnostic
Tools Conference Date: Wednesday, February 16, 2022 Time: 4:30
PM ET
About Biodesix Biodesix is a leading data-driven
diagnostic solutions company with a focus in lung disease. The
Company develops diagnostic tests addressing important clinical
questions by combining multi-omics through the power of artificial
intelligence. Biodesix is the first company to offer eight
non-invasive tests for patients with lung diseases. The blood based
Nodify Lung® nodule risk assessment testing strategy, consisting of
the Nodify XL2® and the Nodify CDT® tests, evaluates the risk of
malignancy in incidental pulmonary nodules, enabling physicians to
better triage patients to the most appropriate course of action.
The blood based IQLung™ strategy for lung cancer patients
integrates the GeneStrat® targeted test, the GeneStrat NGS™ test
and the VeriStrat® test to support treatment decisions across all
stages of lung cancer with results in an unprecedented 36-72 hours,
expediting time to treatment. Biodesix also leverages the
proprietary and advanced Diagnostic Cortex® AI (Artificial
Intelligence) platform, to collaborate with many of the world’s
leading biotechnology and pharmaceutical companies to solve complex
diagnostic challenges in lung disease. Biodesix launched the
SARS-CoV-2 ddPCR™ test, the Platelia SARS-CoV-2 Total Ab, and the
cPass™ SARS-CoV-2 Neutralization Antibody test (cPass™
Neutralization Test Kit, GenScript, Inc,) in response to the global
pandemic and virus that impacts the lung and causes COVID-19. For
more information about Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that
involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform
Act of 1995. All statements contained in this press release other
than statements of historical fact, are forward-looking statements.
The words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, it is possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. Factors that could cause actual results
to differ materially from those contemplated in this press release
can be found in the Risk Factors section of Biodesix’s most recent
annual report on Form 10-K, filed March 16, 2021, or subsequent
quarterly reports on Form 10-Q during 2021, if applicable. Biodesix
undertakes no obligation to revise or publicly release the results
of any revision to such forward-looking statements, except as
required by law. Given these risks and uncertainties, readers are
cautioned not to place undue reliance on such forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220209005276/en/
Media: Bobbi Coffin bobbi.coffin@biodesix.com (303)
892-3203
Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024